BofA analyst Kevin Fischbeck downgraded Option Care Health (OPCH) to Neutral from Buy with a price target of $29, down from $43. While the earnings print was in line and 2024 EBITDA guidance was roughly unchanged, Option Care “sounded cautious” on the 2025 outlook given the potential material pressure to gross margins on Stelara, the analyst tells investors. The company is not able to quantify the potential impact as it continues to negotiate on planned changes, which creates uncertainty, says the analyst, who cites both lower estimates and a lower multiple for the firm’s lower rating and price target
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health downgraded to Neutral from Buy at BofA
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- Option Care Health sees ‘drastic,’ ‘rapid’ impact in early 2025 from biosimilars
- Option Care Health reports Q3 adjusted EPS 41c, consensus 31c
- Option Care Health sees FY24 revenue $4.9B-$4.95B, consensus $4.83B